Cato Elisabeth Andree Corsten
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Cato Elisabeth Andree Corsten has a total of 53 co-authors. Here are the top co-authors by number of shared publications:
- Joost Smolders
Department of Immunology, MS Center ErasMS, Erasmus MC, University Medical Center, Rotterdam, The Netherlands
9 shared publications Ana M. Marques
Department of Immunology, MS Center ErasMS, Erasmus MC University Medical Center Rotterdam, Dr. Molewaterplein 40, 3015 GD, Rotterdam, the Netherlands
4 shared publications- Beatrijs Wokke
Department of Neurology, Erasmus Medical Center, Rotterdam, The Netherlands
4 shared publications Beatrijs Wokke
Department of Neurology, MS Center ErasMS, Erasmus MC University Medical Center Rotterdam, Dr. Molewaterplein 40, 3015 GD, Rotterdam, the Netherlands
3 shared publications- Ide Smets
Department of Neurology, MS Center ErasMS Erasmus Medisch Centrum Rotterdam the Netherlands
3 shared publications Jeroen van Rooij
Department of Internal Medicine, Erasmus MC University Medical Center Rotterdam, Dr. Molewaterplein 40, 3015 GD, Rotterdam, the Netherlands
2 shared publications
Latest Publications
- Open Access
- 28 February 2026
- Published by Elsevier in Multiple Sclerosis and Related Disorders
- Vol. 109, 107101
Genetic and environmental mediators of multiple sclerosis susceptibility but not early severity run in families
- 28 February 2026
- Published by Elsevier in Multiple Sclerosis and Related Disorders
- Vol. 109, 107101
Open AccessGenetic and environmental mediators of multiple sclerosis susceptibility but not early severity run in families
- Open Access
- 9 February 2026
- Published by Springer Nature in Journal of Neurology
- Vol. 273 (2) , 128
Serum neurofilament light chain and glial fibrillary acidic protein predicting multiple sclerosis after clinically isolated syndrome
Introduction: Serum neurofilament light chain (NfL) and glial fibrillary acidic protein (GFAP) may synergistically enhance early risk stratification of multiple sclerosis (MS) diagnosis after clinically isolated syndromes (CIS). We investigated the prognostic value of combined NfL and GFAP for McDonald 2024 MS diagnosis after CIS and associations with key genetic and environmental risk factors. Methods: CIS participants, within six months after symptom onset, were included in a prospective cohort. We measured baseline serum NfL and GFAP levels and calculated z-scores. We evaluated weighted genetic risk scores for MS susceptibility, HLA-DRB1*15:01 risk and measured Anti-Epstein Barr virus Nuclear Antigen-1 (anti-EBNA1) immunoglobulin G (IgG) antibodies. Associations with MS diagnosis were evaluated using Cox proportional hazards models and time-dependent receiver operating characteristic (ROC) analyses. Results: During follow-up, 162/221 CIS participants were diagnosed with McDonald 2024 MS. Separately, high NfL and GFAP associated with earlier MS diagnoses (hazard ratio (HR) 1.36, 95% confidence interval (CI) 1.12–1.66, p = 0.002, HR 1.12, 95% CI 1.02–1.42, p = 0.01, respectively). In combined models, only NfL remained independently predictive (HR 1.30, 95% CI 1.02–1.60, p = 0.01). Time-dependent ROC analyses showed similar results for NfL alone and combined with GFAP. HLA-DRB1*15:01-risk, but not GFAP or anti-EBNA1 IgG, improved predictive value. Conclusion: Our study found that serum NfL outperformed GFAP in predicting early MS diagnoses after CIS. Baseline NfL, together with HLA-DRB1*15:01 status, provides robust early risk stratification for MS after CIS, whereas GFAP and anti-EBNA1 titres add limited prognostic value. Additional immunological and imaging markers are essential to further refine predictive models.
- 9 February 2026
- Published by Springer Nature in Journal of Neurology
- Vol. 273 (2) , 128
Open AccessSerum neurofilament light chain and glial fibrillary acidic protein predicting multiple sclerosis after clinically isolated syndrome
Introduction: Serum neurofilament light chain (NfL) and glial fibrillary acidic protein (GFAP) may synergistically enhance early risk stratification of multiple sclerosis (MS) diagnosis after clinically isolated syndromes (CIS). We investigated the prognostic value of combined NfL and GFAP for McDonald 2024 MS diagnosis after CIS and associations with key genetic and environmental risk factors. Methods: CIS participants, within six months after symptom onset, were included in a prospective cohort. We measured baseline serum NfL and GFAP levels and calculated z-scores. We evaluated weighted genetic risk scores for MS susceptibility, HLA-DRB1*15:01 risk and measured Anti-Epstein Barr virus Nuclear Antigen-1 (anti-EBNA1) immunoglobulin G (IgG) antibodies. Associations with MS diagnosis were evaluated using Cox proportional hazards models and time-dependent receiver operating characteristic (ROC) analyses. Results: During follow-up, 162/221 CIS participants were diagnosed with McDonald 2024 MS. Separately, high NfL and GFAP associated with earlier MS diagnoses (hazard ratio (HR) 1.36, 95% confidence interval (CI) 1.12–1.66, p = 0.002, HR 1.12, 95% CI 1.02–1.42, p = 0.01, respectively). In combined models, only NfL remained independently predictive (HR 1.30, 95% CI 1.02–1.60, p = 0.01). Time-dependent ROC analyses showed similar results for NfL alone and combined with GFAP. HLA-DRB1*15:01-risk, but not GFAP or anti-EBNA1 IgG, improved predictive value. Conclusion: Our study found that serum NfL outperformed GFAP in predicting early MS diagnoses after CIS. Baseline NfL, together with HLA-DRB1*15:01 status, provides robust early risk stratification for MS after CIS, whereas GFAP and anti-EBNA1 titres add limited prognostic value. Additional immunological and imaging markers are essential to further refine predictive models.
- Open Access
- 20 January 2026
- Published by Ubiquity Press, Ltd. in Perspectives on Medical Education
- Vol. 15 (1) , 600-620
Ethical Guidance for Medical Schools and Medical Students in High-Income Countries for Clinical Electives in Low- and Middle-Income Countries: A Systematic Review
Introduction: Academic interest in ethical guidance for medical students from High-Income Countries (HICs) undertaking clinical electives in Low- and Middle-Income Countries (LMICs) has increased. Earlier ethical frameworks laid important groundwork but predate contemporary debates on social justice in global health. This study reviews recent literature to assess how these debates shape and produce ethical guidance, distinguish between ethical student conduct and elective programs, and how such guidance is translated into practice. Methods: A systematic review was conducted on ethical guidance for HIC medical schools and students regarding LMIC electives. Articles published between January 2018 and October 2023 were identified from PubMed, Embase, and Global Health. Thematic synthesis was combined with analysis of authorship (pose) and intended audience (gaze). Results: Of 711 articles, 24 met inclusion criteria. Five interconnecting themes emerged: humility, reflection, local embeddedness, equitable partnerships, and student health and well-being. While these align with existing frameworks, guidance remains largely conceptual, with limited attention to implementation and accountability across ethical student conduct and program design, with responsibility predominantly located at the level of HIC students. Pose and gaze analysis revealed epistemic imbalances in authorship and intended audiences. Most articles reflected HIC-based perspectives, with North American authors overrepresented and no solely LMIC-authored articles. Discussion: Ethical guidance remains dominated by HIC perspectives and focused on student conduct rather than program structures. By distinguishing between individual and institutional ethics, this study highlights the need for actionable, co-created frameworks that address accountability, equity, and sustainability in LMIC electives, including attention to institutional responsibility and LMIC perspectives.
- 20 January 2026
- Published by Ubiquity Press, Ltd. in Perspectives on Medical Education
- Vol. 15 (1) , 600-620
Open AccessEthical Guidance for Medical Schools and Medical Students in High-Income Countries for Clinical Electives in Low- and Middle-Income Countries: A Systematic Review
Introduction: Academic interest in ethical guidance for medical students from High-Income Countries (HICs) undertaking clinical electives in Low- and Middle-Income Countries (LMICs) has increased. Earlier ethical frameworks laid important groundwork but predate contemporary debates on social justice in global health. This study reviews recent literature to assess how these debates shape and produce ethical guidance, distinguish between ethical student conduct and elective programs, and how such guidance is translated into practice. Methods: A systematic review was conducted on ethical guidance for HIC medical schools and students regarding LMIC electives. Articles published between January 2018 and October 2023 were identified from PubMed, Embase, and Global Health. Thematic synthesis was combined with analysis of authorship (pose) and intended audience (gaze). Results: Of 711 articles, 24 met inclusion criteria. Five interconnecting themes emerged: humility, reflection, local embeddedness, equitable partnerships, and student health and well-being. While these align with existing frameworks, guidance remains largely conceptual, with limited attention to implementation and accountability across ethical student conduct and program design, with responsibility predominantly located at the level of HIC students. Pose and gaze analysis revealed epistemic imbalances in authorship and intended audiences. Most articles reflected HIC-based perspectives, with North American authors overrepresented and no solely LMIC-authored articles. Discussion: Ethical guidance remains dominated by HIC perspectives and focused on student conduct rather than program structures. By distinguishing between individual and institutional ethics, this study highlights the need for actionable, co-created frameworks that address accountability, equity, and sustainability in LMIC electives, including attention to institutional responsibility and LMIC perspectives.
- Open Access
- 5 January 2026
- Published by Wiley in Annals of Neurology
- Vol. 99 (4) , 1083-1089
Brain Atrophy Associated With Risk Variant rs10191329 Extends Beyond Multiple Sclerosis
The risk allele rs10191329*A is associated with disease severity and brain atrophy in people with multiple sclerosis (MS). We investigated the association of rs10191329 with age‐related brain atrophy in a population‐based cohort using 10,308 magnetic resonance imaging (MRI) scans of 4,815 participants aged ≥ 45 years without MS in cross‐sectional and longitudinal analyses. We observed associations between the rs10191329*A allele and lower total brain volume and gray matter volume in middle‐aged (< 55 years of age), but not in older participants. These data suggest that rs10191329*A contributes to earlier onset of atrophy in the general population, and that mediating mechanisms of accelerated neurodegeneration extend beyond MS. ANN NEUROL 2026;99:1083–1089
- 5 January 2026
- Published by Wiley in Annals of Neurology
- Vol. 99 (4) , 1083-1089
Open AccessBrain Atrophy Associated With Risk Variant rs10191329 Extends Beyond Multiple Sclerosis
The risk allele rs10191329*A is associated with disease severity and brain atrophy in people with multiple sclerosis (MS). We investigated the association of rs10191329 with age‐related brain atrophy in a population‐based cohort using 10,308 magnetic resonance imaging (MRI) scans of 4,815 participants aged ≥ 45 years without MS in cross‐sectional and longitudinal analyses. We observed associations between the rs10191329*A allele and lower total brain volume and gray matter volume in middle‐aged (< 55 years of age), but not in older participants. These data suggest that rs10191329*A contributes to earlier onset of atrophy in the general population, and that mediating mechanisms of accelerated neurodegeneration extend beyond MS. ANN NEUROL 2026;99:1083–1089
- Open Access
Multiple sclerosis-associated HLA demarcates EBV-specific CD8 + T cells with an exhausted and brain residency phenotype
Specific HLA class I subtypes as well as circulating antibodies against Epstein-Barr virus (EBV) have been associated with increased susceptibility to develop multiple sclerosis (MS). It is currently unclear whether and how these risk factors are functionally related. Here, we assessed the impact of MS risk allele HLA-B7 and protective allele HLA-A2 on the effector phenotype of EBV-specific CD8 + T cells and if this corresponds with anti-EBV IgG titers. For this, we selected HLA-A2 + and/or HLA-B7 + donors with and without MS and analyzed HLA-restricted, EBV- specific CD8 + T cells with different fine-specificities using 38 color-based spectral flow cytometry. In contrast to HLA-A2-restricted CD8 + T cells, HLA-B7-restricted CD8 + T cells showed a confined response to EBV, which was mainly directed against latent peptide EBNA3A(379-387). These HLA-B7-restricted EBV-specific CD8 + T cells expressed higher levels of CNS residency markers CXCR3 and CD20 and were most abundant in fresh single-cell suspensions derived from different post-mortem CNS compartments of an HLA-A2 + B7 + MS donor. Moreover, HLA-B7- restricted EBV-specific CD8 + T cells displayed a more exhausted phenotype (PD- 1 + CD244 + CD160 + KLRG1 + TIGIT + ) that stood out in the blood from people with MS (pwMS). Accordingly, in the blood, increased IgG titers against EBV were found for pwMS carrying HLA- B7 but lacking HLA-A2, which seemed to coincide with HLA-B7-restricted EBV-specific CD8 + T cells having such an effector phenotype. These data support a model in which the confined response against EBV makes circulating HLA-B7-restricted CD8 + T cells less able to control EBV and more prone to infiltrate the CNS in pwMS.
Open AccessMultiple sclerosis-associated HLA demarcates EBV-specific CD8 + T cells with an exhausted and brain residency phenotype
Specific HLA class I subtypes as well as circulating antibodies against Epstein-Barr virus (EBV) have been associated with increased susceptibility to develop multiple sclerosis (MS). It is currently unclear whether and how these risk factors are functionally related. Here, we assessed the impact of MS risk allele HLA-B7 and protective allele HLA-A2 on the effector phenotype of EBV-specific CD8 + T cells and if this corresponds with anti-EBV IgG titers. For this, we selected HLA-A2 + and/or HLA-B7 + donors with and without MS and analyzed HLA-restricted, EBV- specific CD8 + T cells with different fine-specificities using 38 color-based spectral flow cytometry. In contrast to HLA-A2-restricted CD8 + T cells, HLA-B7-restricted CD8 + T cells showed a confined response to EBV, which was mainly directed against latent peptide EBNA3A(379-387). These HLA-B7-restricted EBV-specific CD8 + T cells expressed higher levels of CNS residency markers CXCR3 and CD20 and were most abundant in fresh single-cell suspensions derived from different post-mortem CNS compartments of an HLA-A2 + B7 + MS donor. Moreover, HLA-B7- restricted EBV-specific CD8 + T cells displayed a more exhausted phenotype (PD- 1 + CD244 + CD160 + KLRG1 + TIGIT + ) that stood out in the blood from people with MS (pwMS). Accordingly, in the blood, increased IgG titers against EBV were found for pwMS carrying HLA- B7 but lacking HLA-A2, which seemed to coincide with HLA-B7-restricted EBV-specific CD8 + T cells having such an effector phenotype. These data support a model in which the confined response against EBV makes circulating HLA-B7-restricted CD8 + T cells less able to control EBV and more prone to infiltrate the CNS in pwMS.
- 16 July 2024
- Published by Oxford University Press (OUP) in Brain
- Vol. 147 (10) , e64-e65
Putative benefits of vitamin D supplements in multiple sclerosis out of reach due to sample size
Cato E A Corsten, Beatrijs H A Wokke, Joost Smolders; Putative benefits of vitamin D supplements in multiple sclerosis out of reach due to sample size, Bra
- 16 July 2024
- Published by Oxford University Press (OUP) in Brain
- Vol. 147 (10) , e64-e65
Putative benefits of vitamin D supplements in multiple sclerosis out of reach due to sample size
Cato E A Corsten, Beatrijs H A Wokke, Joost Smolders; Putative benefits of vitamin D supplements in multiple sclerosis out of reach due to sample size, Bra
- Open Access
- 22 October 2023
- Published by Elsevier in Multiple Sclerosis and Related Disorders
- Vol. 80, 105100
Benefits of sphingosine-1-phosphate receptor modulators in relapsing MS estimated with a treatment sequence model
- 22 October 2023
- Published by Elsevier in Multiple Sclerosis and Related Disorders
- Vol. 80, 105100
Open AccessBenefits of sphingosine-1-phosphate receptor modulators in relapsing MS estimated with a treatment sequence model
- Open Access
- 24 July 2023
- Published by SAGE Publications in Multiple Sclerosis Journal – Experimental, Translational and Clinical
- Vol. 9 (3)
Health-economic benefits of anti-CD20 treatments in relapsing multiple sclerosis estimated using a treatment-sequence model
Background: In high-income countries, four anti-CD20 monoclonal antibodies (mAbs) are used or in the pipeline for relapsing MS: ocrelizumab, ofatumumab (both registered), ublituximab (awaiting registration) and rituximab (off-label). List prices differ significantly between registered and off-label drugs. Objective: Comparing differences in benefits between anti-CD20 mAbs from a health-economic and societal perspective. Methods: To reflect lifetime use of DMTs, we used a treatment-sequence model to compare ocrelizumab/ofatumumab and eight other drug classes in terms of health (lifetime relapses, time to Expanded Disability Status Scale [EDSS] 6, lifetime quality-adjusted life years) and cost-effectiveness (net health benefit). To become cost-effective compared to ocrelizumab, we modelled the list price of ublituximab and desired effect on EDSS progression of rituximab. Results: Although drug sequences with ocrelizumab in first- and second-line were more cost-effective than ofatumumab, our probabilistic analysis suggests this outcome was very uncertain. To be more cost-effective than ocrelizumab, ublituximab needs to be about 25% cheaper whilst rituximab needs to equal the effect on disability progression seen with first-line treatments. Conclusions: Our model showed no clear difference in cost-effectiveness between ocrelizumab and ofatumumab. Hence, prescribing the least costly anti-CD20 mAb can democratise MS care without a loss in health benefits.
- 24 July 2023
- Published by SAGE Publications in Multiple Sclerosis Journal – Experimental, Translational and Clinical
- Vol. 9 (3)
Open AccessHealth-economic benefits of anti-CD20 treatments in relapsing multiple sclerosis estimated using a treatment-sequence model
Background: In high-income countries, four anti-CD20 monoclonal antibodies (mAbs) are used or in the pipeline for relapsing MS: ocrelizumab, ofatumumab (both registered), ublituximab (awaiting registration) and rituximab (off-label). List prices differ significantly between registered and off-label drugs. Objective: Comparing differences in benefits between anti-CD20 mAbs from a health-economic and societal perspective. Methods: To reflect lifetime use of DMTs, we used a treatment-sequence model to compare ocrelizumab/ofatumumab and eight other drug classes in terms of health (lifetime relapses, time to Expanded Disability Status Scale [EDSS] 6, lifetime quality-adjusted life years) and cost-effectiveness (net health benefit). To become cost-effective compared to ocrelizumab, we modelled the list price of ublituximab and desired effect on EDSS progression of rituximab. Results: Although drug sequences with ocrelizumab in first- and second-line were more cost-effective than ofatumumab, our probabilistic analysis suggests this outcome was very uncertain. To be more cost-effective than ocrelizumab, ublituximab needs to be about 25% cheaper whilst rituximab needs to equal the effect on disability progression seen with first-line treatments. Conclusions: Our model showed no clear difference in cost-effectiveness between ocrelizumab and ofatumumab. Hence, prescribing the least costly anti-CD20 mAb can democratise MS care without a loss in health benefits.
- Open Access
Benefits of sphingosine-1-phosphate receptor modulators in relapsing MS estimated with a treatment sequence model
Background Three sphingosine-1-phosphate receptor (S1PR) modulators are currently available as disease-modifying therapies (DMTs) for relapsing MS in the Netherlands (i.e. fingolimod, ozanimod and ponesimod). We aimed to identify which S1PR modulator yields the highest benefit from a health-economic and societal perspective during a patient’s lifespan. Methods Incorporating Dutch DMT list prices, we used the ErasmusMC/iMTA MS model to compare DMT sequences, including S1PR modulators and eight other DMT classes, for treatment-naive patients with relapsing MS in terms of health outcomes (number of lifetime relapses, time to Expanded Disability Status Scale (EDSS) 6, lifetime quality-adjusted life years (QALYs)) and cost-effectiveness (net health benefit (NHB)). We estimated the influence of list price and EDSS progression on cost-effectiveness outcomes. Results In deterministic and probabilistic analysis, DMT sequences with ponesimod have lower lifetime costs and higher QALYs resulting in a higher average NHB compared to sequences with other S1PR modulators. Ponesimod remains the most cost-effective S1PR modulator when EDSS progression is class-averaged. Given the variable effects on disability progression, list price reductions could make fingolimod but not ozanimod more cost-effective than ponesimod. Conclusion Our model favours ponesimod among the S1PR modulators for the treatment of relapsing MS. This implies that prioritizing ponesimod over other S1PR modulators translates into a more efficacious spending of national healthcare budget without reducing benefit for people with MS. Prioritizing cost-effective choices when counselling patients contributes to affordable and accessible MS care. Highlights Disease-modifying therapies (DMTs) are the largest cost driver in MS Three sphingosine-1-phosphate receptor (S1PR) modulators are used for relapsing MS Our model compares sequences of up to 5 DMTs in terms of health (relapses, progression) and costs Comparing sequences including S1PR modulators, ponesimod is the most cost-effective drug Cost-effectiveness research helps to prioritize when prescribing drugs of a similar class
Open AccessBenefits of sphingosine-1-phosphate receptor modulators in relapsing MS estimated with a treatment sequence model
Background Three sphingosine-1-phosphate receptor (S1PR) modulators are currently available as disease-modifying therapies (DMTs) for relapsing MS in the Netherlands (i.e. fingolimod, ozanimod and ponesimod). We aimed to identify which S1PR modulator yields the highest benefit from a health-economic and societal perspective during a patient’s lifespan. Methods Incorporating Dutch DMT list prices, we used the ErasmusMC/iMTA MS model to compare DMT sequences, including S1PR modulators and eight other DMT classes, for treatment-naive patients with relapsing MS in terms of health outcomes (number of lifetime relapses, time to Expanded Disability Status Scale (EDSS) 6, lifetime quality-adjusted life years (QALYs)) and cost-effectiveness (net health benefit (NHB)). We estimated the influence of list price and EDSS progression on cost-effectiveness outcomes. Results In deterministic and probabilistic analysis, DMT sequences with ponesimod have lower lifetime costs and higher QALYs resulting in a higher average NHB compared to sequences with other S1PR modulators. Ponesimod remains the most cost-effective S1PR modulator when EDSS progression is class-averaged. Given the variable effects on disability progression, list price reductions could make fingolimod but not ozanimod more cost-effective than ponesimod. Conclusion Our model favours ponesimod among the S1PR modulators for the treatment of relapsing MS. This implies that prioritizing ponesimod over other S1PR modulators translates into a more efficacious spending of national healthcare budget without reducing benefit for people with MS. Prioritizing cost-effective choices when counselling patients contributes to affordable and accessible MS care. Highlights Disease-modifying therapies (DMTs) are the largest cost driver in MS Three sphingosine-1-phosphate receptor (S1PR) modulators are used for relapsing MS Our model compares sequences of up to 5 DMTs in terms of health (relapses, progression) and costs Comparing sequences including S1PR modulators, ponesimod is the most cost-effective drug Cost-effectiveness research helps to prioritize when prescribing drugs of a similar class
- Open Access
Distinct Effector Programs of Brain-Homing CD8+ T Cells in Multiple Sclerosis
The effector programs of CD8+ memory T cells are influenced by the transcription factors RUNX3, EOMES and T-bet. How these factors define brain-homing CD8+ memory T cells in multiple sclerosis (MS) remains unknown. To address this, we analyzed blood, CSF and brain tissues from MS patients for the impact of differential RUNX3, EOMES and T-bet expression on CD8+ T cell effector phenotypes. The frequencies of RUNX3- and EOMES-, but not T-bet-expressing CD8+ memory T cells were reduced in the blood of treatment-naïve MS patients as compared to healthy controls. Such reductions were not seen in MS patients treated with natalizumab (anti-VLA-4 Ab). We found an additional loss of T-bet in RUNX3-expressing cells, which was associated with the presence of MS risk SNP rs6672420 (RUNX3). RUNX3+EOMES+T-bet− CD8+ memory T cells were enriched for the brain residency-associated markers CCR5, granzyme K, CD20 and CD69 and selectively dominated the MS CSF. In MS brain tissues, T-bet coexpression was recovered in CD20dim and CD69+ CD8+ T cells, and was accompanied by increased coproduction of granzyme K and B. These results indicate that coexpression of RUNX3 and EOMES, but not T-bet, defines CD8+ memory T cells with a pre-existing brain residency-associated phenotype such that they are prone to enter the CNS in MS.
Open AccessDistinct Effector Programs of Brain-Homing CD8+ T Cells in Multiple Sclerosis
The effector programs of CD8+ memory T cells are influenced by the transcription factors RUNX3, EOMES and T-bet. How these factors define brain-homing CD8+ memory T cells in multiple sclerosis (MS) remains unknown. To address this, we analyzed blood, CSF and brain tissues from MS patients for the impact of differential RUNX3, EOMES and T-bet expression on CD8+ T cell effector phenotypes. The frequencies of RUNX3- and EOMES-, but not T-bet-expressing CD8+ memory T cells were reduced in the blood of treatment-naïve MS patients as compared to healthy controls. Such reductions were not seen in MS patients treated with natalizumab (anti-VLA-4 Ab). We found an additional loss of T-bet in RUNX3-expressing cells, which was associated with the presence of MS risk SNP rs6672420 (RUNX3). RUNX3+EOMES+T-bet− CD8+ memory T cells were enriched for the brain residency-associated markers CCR5, granzyme K, CD20 and CD69 and selectively dominated the MS CSF. In MS brain tissues, T-bet coexpression was recovered in CD20dim and CD69+ CD8+ T cells, and was accompanied by increased coproduction of granzyme K and B. These results indicate that coexpression of RUNX3 and EOMES, but not T-bet, defines CD8+ memory T cells with a pre-existing brain residency-associated phenotype such that they are prone to enter the CNS in MS.